Christopher S Lathan1, Angel Cronin2, Reginald Tucker-Seeley2, S Yousuf Zafar2, John Z Ayanian2, Deborah Schrag2. 1. Christopher S. Lathan, Angel Cronin, Reginald Tucker-Seeley, and Deborah Schrag, Dana-Farber Cancer Institute, Boston, MA; S. Yousuf Zafar, Duke University School of Medicine; John Z. Ayanian, University of Michigan; and Reginald Tucker-Seeley, Harvard T.H. Chan School of Public Health. christopher_lathan@dfci.harvard.edu. 2. Christopher S. Lathan, Angel Cronin, Reginald Tucker-Seeley, and Deborah Schrag, Dana-Farber Cancer Institute, Boston, MA; S. Yousuf Zafar, Duke University School of Medicine; John Z. Ayanian, University of Michigan; and Reginald Tucker-Seeley, Harvard T.H. Chan School of Public Health.
Abstract
PURPOSE: To measure the association between patient financial strain and symptom burden and quality of life (QOL) for patients with new diagnoses of lung or colorectal cancer. PATIENTS AND METHODS: Patients participating in the Cancer Care Outcomes Research and Surveillance study were interviewed about their financial reserves, QOL, and symptom burden at 4 months of diagnosis and, for survivors, at 12 months of diagnosis. We assessed the association of patient-reported financial reserves with patient-reported outcomes including the Brief Pain Inventory, symptom burden on the basis of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30, and QOL on the basis of the EuroQoL-5 Dimension scale. Multivariable linear regression models were fit for each outcome and cancer type, adjusting for age, race/ethnicity, sex, income, insurance, stage at diagnosis, and comorbidity. RESULTS: Among patients with lung and colorectal cancer, 40% and 33%, respectively, reported limited financial reserves (≤ 2 months). Relative to patients with more than 12 months of financial reserves, those with limited financial reserves reported significantly increased pain (adjusted mean difference, 5.03 [95% CI, 3.29 to 7.22] and 3.45 [95% CI, 1.25 to 5.66], respectively, for lung and colorectal), greater symptom burden (5.25 [95% CI, 3.29 to .22] and 5.31 [95% CI, 3.58 to 7.04]), and poorer QOL (4.70 [95% CI, 2.82 to 6.58] and 5.22 [95% CI, 3.61 to 6.82]). With decreasing financial reserves, a clear dose-response relationship was present across all measures of well-being. These associations were also manifest for survivors reporting outcomes again at 1 year and persisted after adjustment for stage, comorbidity, insurance, and other clinical attributes. CONCLUSION: Patients with cancer and limited financial reserves are more likely to have higher symptom burden and decreased QOL. Assessment of financial reserves may help identify patients who need intensive support.
PURPOSE: To measure the association between patient financial strain and symptom burden and quality of life (QOL) for patients with new diagnoses of lung or colorectal cancer. PATIENTS AND METHODS: Patients participating in the Cancer Care Outcomes Research and Surveillance study were interviewed about their financial reserves, QOL, and symptom burden at 4 months of diagnosis and, for survivors, at 12 months of diagnosis. We assessed the association of patient-reported financial reserves with patient-reported outcomes including the Brief Pain Inventory, symptom burden on the basis of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30, and QOL on the basis of the EuroQoL-5 Dimension scale. Multivariable linear regression models were fit for each outcome and cancer type, adjusting for age, race/ethnicity, sex, income, insurance, stage at diagnosis, and comorbidity. RESULTS: Among patients with lung and colorectal cancer, 40% and 33%, respectively, reported limited financial reserves (≤ 2 months). Relative to patients with more than 12 months of financial reserves, those with limited financial reserves reported significantly increased pain (adjusted mean difference, 5.03 [95% CI, 3.29 to 7.22] and 3.45 [95% CI, 1.25 to 5.66], respectively, for lung and colorectal), greater symptom burden (5.25 [95% CI, 3.29 to .22] and 5.31 [95% CI, 3.58 to 7.04]), and poorer QOL (4.70 [95% CI, 2.82 to 6.58] and 5.22 [95% CI, 3.61 to 6.82]). With decreasing financial reserves, a clear dose-response relationship was present across all measures of well-being. These associations were also manifest for survivors reporting outcomes again at 1 year and persisted after adjustment for stage, comorbidity, insurance, and other clinical attributes. CONCLUSION:Patients with cancer and limited financial reserves are more likely to have higher symptom burden and decreased QOL. Assessment of financial reserves may help identify patients who need intensive support.
Authors: Janneke P C Grutters; Manuela A Joore; Erwin M Wiegman; Johannes A Langendijk; Dirk de Ruysscher; Monique Hochstenbag; Anita Botterweck; Philippe Lambin; Madelon Pijls-Johannesma Journal: Thorax Date: 2010-10 Impact factor: 9.139
Authors: S Yousuf Zafar; Jeffrey M Peppercorn; Deborah Schrag; Donald H Taylor; Amy M Goetzinger; Xiaoyin Zhong; Amy P Abernethy Journal: Oncologist Date: 2013-02-26
Authors: Reshma Jagsi; John A E Pottow; Kent A Griffith; Cathy Bradley; Ann S Hamilton; John Graff; Steven J Katz; Sarah T Hawley Journal: J Clin Oncol Date: 2014-03-24 Impact factor: 44.544
Authors: L Bennett; Z Zhao; B Barber; X Zhou; M Peeters; J Zhang; F Xu; J Wiezorek; J-Y Douillard Journal: Br J Cancer Date: 2011-10-11 Impact factor: 7.640
Authors: Theresa A Hastert; Jaclyn M Kyko; Amanda R Reed; Felicity W K Harper; Jennifer L Beebe-Dimmer; Tara E Baird; Ann G Schwartz Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-05-06 Impact factor: 4.254
Authors: Kathleen A Lynch; Nicholas Emard; Kevin T Liou; Karen Popkin; Michael Borten; Ogechi Nwodim; Thomas M Atkinson; Jun J Mao Journal: J Pain Symptom Manage Date: 2020-11-19 Impact factor: 3.612
Authors: Ryan D Nipp; Amy M Shui; Giselle K Perez; Anne C Kirchhoff; Jeffrey M Peppercorn; Beverly Moy; Karen Kuhlthau; Elyse R Park Journal: JAMA Oncol Date: 2018-06-01 Impact factor: 31.777
Authors: Tania Jaber; Steven G Waguespack; Maria E Cabanillas; Mohamed Elbanan; Thinh Vu; Ramona Dadu; Steven I Sherman; Moran Amit; Elmer B Santos; Mark Zafereo; Naifa L Busaidy Journal: J Clin Endocrinol Metab Date: 2018-10-01 Impact factor: 5.958
Authors: Sara Bouberhan; Meghan Shea; Alice Kennedy; Adrienne Erlinger; Hannah Stack-Dunnbier; Mary K Buss; Laureen Moss; Kathleen Nolan; Christopher Awtrey; John L Dalrymple; Leslie Garrett; Fong W Liu; Michele R Hacker; Katharine M Esselen Journal: Gynecol Oncol Date: 2019-04-30 Impact factor: 5.482